Preclinical Safety Profile of an Oral Naringenin/Hesperidin Dosage Form by In Vivo Toxicological Tests

• Asıl Yazarlar: Carla Georgina Cicero-Sarmiento (Yazar), Rolffy Ortiz-Andrade (Yazar), Jesús Alfredo Araujo-León (Yazar), Maira Rubí Segura-Campos (Yazar), Priscila Vazquez-Garcia (Yazar), Héctor Rubio-Zapata (Yazar), Efrén Hernández-Baltazar (Yazar), Victor Yañez-Pérez (Yazar), Amanda Sánchez-Recillas (Yazar), Juan Carlos Sánchez-Salgado (Yazar), Emanuel Hernández-Núñez (Yazar), Durcy Ruiz-Ciau (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: MDPI AG, 2022-05-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

We developed a naringenin-hesperidin molar mixture (MIX-160) with proven antihyperglycemic and vasorelaxant activity in preclinical studies. A solid dosage form was manufactured to improve the bioavailability properties. In the current study, we sought to evaluate the oral preclinical toxicity of th...